MEDI9197 clinical trials
How each study uses MEDI9197 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MEDI9197 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
2 studies that test it; most in 2015 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
National Institute of Allergy and Infectious Diseases (NIAID) (1) · HIV Vaccine Trials Network (1) · MedImmune LLC (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test MEDI9197.
- Jun 2027Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But UninfectedPhase 1 · HIV Vaccine Trials Network
Studies
Open first, then newest update. How each study uses MEDI9197 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But UninfectedNot yet recruitingPhase 1HIV Vaccine Trials NetworkNCT06613789Written as 3M-052-AF
- Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT04177355Written as 3M-052-AF
- A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid TumorsTerminatedPhase 1MedImmune LLCNCT02556463Written as MEDI9197
Given beside what is tested · 3 — MEDI9197 is usual care or a partner of the new treatment
- Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy AdultsCompletedPhase 1Valneva Austria GmbHNCT06334393Written as 3M-052-AF
- Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral TherapySuspendedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06680479Written as 3M-052-AF
- Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIVCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05781542Written as 3M-052-AF
Codes
What other systems call MEDI9197 · ClinicalTrials.gg INT000927
- MeSH (NLM) C000626991MEDI9197One source NLM
- UNII (FDA) 16598XQ2BTTELRATOLIMODConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626991 | MEDI9197 | One source NLM |
| UNII (FDA) | 16598XQ2BT | TELRATOLIMOD | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.